Anixa Biosciences Inc. (ANIX)
NASDAQ: ANIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ANIX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $84.82M
- EPS (TTM)
- -$0.32
- Dividend yield
- None
- 52-week range
- 2.32 – 5.46
- Day range
- 2.40 – 2.59
- Volume / Avg
- 355.05K / 282.29K
- Beta
- —
- Shares outstanding
- 34.76M
52-week range
ANIX stock today
Shares of Anixa Biosciences (ANIX) finished lower on Nov 20 at $2.44, a drop of 6.15% or $0.16 per share, versus the S&P 500's 3.70% decline. At this level, ANIX sits near the bottom of its 52-week range of $2.32 to $5.46: 55.3% below the high, set on Dec 9, 2025 and 5.2% above the low. ANIX is down 21.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 43.8%.
Anixa Biosciences has posted a net loss over the last twelve months (EPS of -$0.32), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Anixa Biosciences
Company profileAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Amit Kumar Ph.D.
- Headquarters
- San Jose, CA
- Employees
- 4
- Website
- anixa.com
Financial highlights
Full financialsAnixa Biosciences reported a net loss of $10.9 million, compared with a loss of $12.6 million a year earlier. Diluted earnings per share came in at -$0.34.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | — | $210.00K | $210.00K | — | $512.00K |
| Growth | — | 0.00% | — | — | — |
| Net income | $-10.93M | $-12.55M | $-9.81M | $-13.60M | $-12.95M |
| EPS (diluted) | $-0.34 | $-0.39 | $-0.32 | $0.45 | $-0.45 |
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$9.67+296.31%
- Strong buy 1
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q3 2026)
- Sep 9, 2026
- EPS actual vs est.
- $-0.08 vs —
ANIX news
All ANIX news- Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical TrialPR Newswire
- Friday 10/23 Insider Buying Report: NVA, ANIXNasdaqNVA, ANIX, LEN.B
- Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus ConferencePR Newswire
Anixa Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| UPBUpstream Bio Inc. | 1.59 | -20.50% | $87.15M | vs ANIX |
| EQEquillium Inc. | 1.06 | -5.36% | $87.26M | vs ANIX |
| OGIOrganigram Global Inc. | 0.583 | -7.40% | $82.27M | vs ANIX |
| HURATuHURA Biosciences Inc. | 1.25 | -8.09% | $82.20M | vs ANIX |
| RTSNRetension Pharmaceuticals Inc. | 10.51 | -19.22% | $87.57M | vs ANIX |
| CPIXCumberland Pharmaceuticals Inc. | 5.84 | -7.30% | $87.57M | vs ANIX |
| NKTXNkarta Inc. | 1.14 | +1.34% | $81.29M | vs ANIX |
| TLSATiziana Life Sciences Ltd. | 0.6206 | -8.14% | $79.45M | vs ANIX |
Indexes, lists and sector
Anixa Biosciences stock FAQ
What is Anixa Biosciences's stock price today?
ANIX last traded at $2.44 as of Nov 20, 4:00 PM EST, down 6.15% on the day. Prices are delayed at least 15 minutes.
Does Anixa Biosciences pay a dividend?
No. Anixa Biosciences does not currently pay a regular cash dividend.
Who is Anixa Biosciences's CEO?
Dr. Amit Kumar Ph.D. is the chief executive officer of Anixa Biosciences Inc., which has about 4 employees.
Has ANIX ever split its stock?
Yes. The most recent ANIX stock split was a 1-for-25 split on Jun 26, 2015, one of 5 splits on record.
What is the ANIX 52-week high?
The 52-week high for ANIX is $5.46 and the 52-week low is $2.32. The stock is currently 55.3% below its high.